1. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revisited. Am J Psychiatry 2000;157:493-505.
2. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998;44:1264-76.
3. Sheehan DV. The anxiety disease. New York: Charles Scribner and Sons, 1983;151.-
4. Rapaport MH, Wolkow RM, Clary CM. Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmacol Bull 1998;34:183-9.
5. Otto MW. Psychosocial approach to treatment-resistant anxiety disorders (presentation). Chantilly, VA: Anxiety Disorders Association of America conference on novel approaches to treatment of refractory anxiety disorders, June 15-16, 2003.
6. Gorman JM, Shear MK, McIntyre JS, Zarin DA. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998;155(May supplement).
7. Lydiard RB, Otto MW, Milrod B. Panic disorder treatment. In: Gabbard, GO (ed). Treatment of psychiatric disorders (3rd ed). Washington, DC: American Psychiatric Press, Inc, 2001;1447-82.
8. Simon NM, Safrens SA, Otto MW, et al. Outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 2002;69:201-8.
9. Yonkers KA, Ellison J, Shera D, et al. Description of antipanic therapy in a prospective longitudinal study. J Clin Psychopharmacol 1996;16:223-32.
10. Pollack MH, Worthington JJ, 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-70.
11. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-6.
12. Simon NM. Pharmacological approach to treatment-resistant anxiety disorders (presentation). Chantilly, VA: Anxiety Disorders Association of America conference on novel approaches to treatment of refractory anxiety disorders, June 15-16, 2003.
13. Hoffart A, Due-Madsen J, Lande B, et al. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 1993;54:481-7.
14. Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002;63:772-7.
15. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9.
16. Hollifield M, Thompson P, Uhlenluth E. Potential efficacy and safety of olanzapine in refractory panic disorder (presentation). San Francisco: American Psychiatric Association annual meeting, 2003.
17. Tiffon L, Coplan J, Papp L, Gorman J. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 1994;55:66-9.
18. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in treatment-refractory patients with panic disorder: an open-label study. Hum Psychopharmacol 2002;17:329-33.
19. Chiu S. Gabapentin treatment response in SSRI-refractory panic disorder (presentation) San Francisco: American Psychiatric Association annual meeting, 2003.
20. Marazziti D, Presta S, Pfanner C, et al. Pramipexole augmentation in panic with agoraphobia. Am J Psychiatry 2001;158:498-9.
